Genmab A/S

WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
CUSIP
372303206
SEDOL
BBC9WC7
CIK
0001434265
www.genmab.com
LEI: 529900MTJPDPE4MHJ122
©
New: Infographics X-Lab
FIGI: BBG004MPKM64
GMAB
Genmab A/S
GICS: - · Sektor: Healthcare · Sub-Sektor: Biotechnology
AI
PROFILER
NAME
Genmab A/S
ISIN
US3723032062
TICKER
GMAB
MIC
XNAS
REUTERS
GMAB.OQ
BLOOMBERG
GMAB US
F&G: 77
6.275,16 S&P · 17,03 Vola-Index · 117.762,71 BTC · 1,16757 EURUSD
BUILD THEMEFOLIO IDEEN TEILEN DISKUTIEREN
HEBEL INVESTIEREN
Financial Intelligence
360° iHub Crowd ATH Tracker Index Tracker ETF TF Spicy X-Billboard
FÜR INVESTOREN
FÜR TRADER
Börsenhandel
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von BusinessWire bereitgestellt.
So., 15.06.2025       Genmab A/S
US3723032062

Genmab A/S (Nasdaq: GMAB) today announced new results from the Phase 1b/2 EPCORE® NHL-2 trial Arm 10 (NCT04663347), evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination with rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in adult patients with relapsed/refractory diffuse large B-cell ...
weiterlesen
Genmab A/S
Research & Analysen Termsheet Terminal
Permalink
Mo., 02.06.2025       Genmab A/S
US3723032062

Genmab A/S (Nasdaq: GMAB) announced today new data from cohort B2 of the Phase 1/2 RAINFOL™-01 trial evaluating rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha (FRα)-targeted, TOPO1-inhibitor antibody-drug conjugate (ADC). The study showed that with a median on-study follow-up of 7.7 months, treatment with Rina-S 100 mg/m2...
weiterlesen
Genmab A/S
Research & Analysen Termsheet Terminal
Permalink
Do., 22.05.2025       Genmab A/S
US3723032062

Genmab A/S (Nasdaq: GMAB) announced today that it will present new research from its comprehensive development program evaluating its late-stage portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 30 to June 3 in Chicago, Illinois. The presentations will include the first disclosure of results ...
weiterlesen
Genmab A/S
Research & Analysen Termsheet Terminal
Permalink
Mi., 14.05.2025       Genmab A/S
US3723032062

Genmab A/S (Nasdaq: GMAB) announced today that it will present 14 abstracts evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, as a monotherapy and in combination across disease settings in patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) at the 30th European Hematology Associ...
weiterlesen
Genmab A/S
Research & Analysen Termsheet Terminal
Permalink
Fr., 02.05.2025       Genmab A/S
US3723032062

Genmab A/S (Nasdaq: GMAB) announced today its intention to submit in the first half of 2025 a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for subcutaneous epcoritamab, a bispecific antibody being investigated in combination with rituximab and lenalidomide (R2) for the treatment of adult patients...
weiterlesen
Genmab A/S
Research & Analysen Termsheet Terminal
Permalink
Mo., 31.03.2025       Genmab A/S
US3723032062

Genmab A/S (Nasdaq: GMAB) announced today that the European Commission (EC) has granted marketing authorization for TIVDAK® (tisotumab vedotin), an antibody-drug conjugate (ADC), as monotherapy treatment for adult patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy. TIVDAK is the first and on...
weiterlesen
Genmab A/S
Research & Analysen Termsheet Terminal
Permalink
Do., 27.03.2025       Genmab A/S
US3723032062

Genmab A/S (Nasdaq: GMAB) today announced that the Japan Ministry of Health, Labour and Welfare has approved TIVDAK® (tisotumab vedotin) for the treatment of advanced or recurrent cervical cancer that has progressed on or after cancer chemotherapy. TIVDAK is the first and only ADC to be approved for people living with cervical cancer in Japan. In...
weiterlesen
Genmab A/S
Research & Analysen Termsheet Terminal
Permalink
Mo., 17.03.2025       Genmab A/S
US3723032062

Genmab A/S (Nasdaq: GMAB) announced today updated data from cohort B1 of the Phase 1/2 RAINFOL-01 study of rinatabart sesutecan (Rina-S®), an investigational folate receptor-alpha (FRα)-targeted, TOPO1 antibody-drug conjugate (ADC) that showed Rina-S 120 mg/m2 every 3 weeks (Q3W) resulted in a confirmed objective response rate (ORR) of 55.6% (95% ...
weiterlesen
Genmab A/S
Research & Analysen Termsheet Terminal
Permalink
Mo., 10.03.2025       Genmab A/S
US3723032062

Genmab A/S (Nasdaq: GMAB) announced today that Johnson & Johnson (J&J) has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 (GEN3014). While the initial HexaBody-CD38 clinical data is promising and showed robust clinical efficacy, following a thorough evalua...
weiterlesen
Genmab A/S
Research & Analysen Termsheet Terminal
Permalink
Do., 20.02.2025       Genmab A/S
US3723032062

Genmab A/S (Nasdaq: GMAB) announced today that the Japan Ministry of Health, Labour and Welfare has approved EPKINLY® (epcoritamab) for the treatment of patients with relapsed or refractory (R/R) follicular lymphoma (FL; Grades 1 to 3A) who have received two or more prior lines of therapy. With this additional indication, EPKINLY is now the first ...
weiterlesen
Genmab A/S
Research & Analysen Termsheet Terminal
Permalink
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Informationen zu Product Placements

 

BARRISTA SMART * AD

P R O D U C T   S U G G E S T I O N S